INNOCARE (09969) announced its interim results for the six months ended June 30, 2025. The group achieved revenue of RMB 731 million, representing a 74.26% year-on-year increase. The adjusted loss for the period was RMB 15.504 million, a 93.62% reduction compared to the same period last year. Loss attributable to shareholders was RMB 30.091 million, down 88.51% year-on-year, with a loss per share of RMB 0.02.

According to the announcement, the revenue increase was primarily driven by strong sales growth of Orelabrutinib and licensing income from Prolium. Orelabrutinib revenue increased 52.8% from RMB 417 million for the six months ended June 30, 2024, to RMB 637 million for the six months ended June 30, 2025, due to expanded coverage and an increase in treated patients.